A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults With Growth Hormone Deficiency

Trial Profile

A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults With Growth Hormone Deficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2014

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions
  • Sponsors Versartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jun 2014 According to Versartis media release, the results of the trial were published in Journal of Clinical Endocrinology & Metabolism 2013.
    • 11 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top